Compare OC & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OC | ELAN |
|---|---|---|
| Founded | 1938 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.2B |
| IPO Year | 2006 | 2018 |
| Metric | OC | ELAN |
|---|---|---|
| Price | $120.95 | $22.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $145.27 | $27.89 |
| AVG Volume (30 Days) | 1.0M | ★ 4.0M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.50 | 0.22 |
| Revenue | N/A | ★ $4,715,000,000.00 |
| Revenue This Year | N/A | $8.21 |
| Revenue Next Year | $3.72 | $5.31 |
| P/E Ratio | ★ $80.48 | $101.64 |
| Revenue Growth | N/A | ★ 6.22 |
| 52 Week Low | $97.53 | $19.40 |
| 52 Week High | $159.91 | $27.98 |
| Indicator | OC | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 32.90 | 37.66 |
| Support Level | $117.15 | $21.89 |
| Resistance Level | $129.58 | $25.21 |
| Average True Range (ATR) | 4.06 | 0.65 |
| MACD | -0.51 | -0.08 |
| Stochastic Oscillator | 4.36 | 18.06 |
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.